NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger

Core Insights - NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of the ITOL-102 cell therapy program for Type 1 Diabetes under the merged entity NewCelX Ltd. following their merger [1][3][4] Group 1: Company Overview - NLS Pharmaceutics is a biopharmaceutical company focused on innovative therapies for central nervous system disorders [5] - Kadimastem is a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes [6] Group 2: ITOL-102 Program - The ITOL-102 program aims to develop a functional, stem-cell-derived pancreatic islet cell therapy to cure Type 1 Diabetes without lifelong immunosuppression [3] - The BIRD Foundation, which has invested over $300 million in joint projects since 1977, will continue to support the ITOL-102 program under NewCelX [2][4] Group 3: Strategic Focus - The merger allows NLS to leverage Kadimastem's advanced stem-cell platform, expanding its pipeline into regenerative and metabolic medicine [4]